OHSU studying vitamin D as treatment for prostate cancer

November 10, 1999

Portland, Ore. -- Researchers at Oregon Health Sciences University are examining the idea that vitamin D may stop the progression, or possibly destroy, prostate cancer.

Through a study funded by the National Institutes of Health, oncologists Tomasz Beer, M.D., and David Henner, M.D., Ph.D., are giving patients with recurring cancer high doses of an active form of the vitamin each week and monitoring their disease level.

"High levels of vitamin D work to inhibit the growth of this cancer in the laboratory," said Beer. "In an earlier study we found that weekly dosing can produce these high levels of vitamin D in the blood of patients and is safe. What we want to establish now is that regular doses of the vitamin can keep the disease under control over the long term."

The study is looking specifically at patients who received initial treatment for their cancer, but had the disease return. "At this stage, these men would be looking at hormone treatments or aggressive chemotherapy, which have severe side effects," said Beer.

Instead, the hope is to use vitamin D to delay aggressive treatment. "We don't really expect to eradicate the disease -- that would be great, but we hope to stop it in its tracks," Beer said.

If the study shows that long-term use of vitamin D poses no risk, patients could theoretically stay on this treatment the rest of their lives to keep the cancer from progressing.

Beer said they are looking for a total of 25 patients to complete the study.

Oregon Health & Science University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.